2-5-1, Nihonbashi-Honcho
Chuo-Ku
Tokyo 103-8411
Japan
81 3 3244 3000
https://www.astellas.com
Sector(s): Healthcare
Industry: Drug Manufacturers - General
Full-time employees:
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Naoki Okamura BSc | President, CEO & Director | 871.62k | N/A | 1962 |
Mr. Atsushi Kitamura | Chief Financial Officer | N/A | N/A | N/A |
Nobue Yasuda | General Manager of Finance & Accounting Department | N/A | N/A | N/A |
Mr. Yoshitsugu Shitaka Ph.D. | Chief Scientific Officer & Senior Managing Executive Officer | N/A | N/A | N/A |
Ms. Catherine B. Levitt | General Counsel | N/A | N/A | N/A |
Mr. Katsuyoshi Sugita | Chief People Officer, Chief Ethics & Compliance Officer, EVP of HR and Representative Director | N/A | N/A | 1967 |
Mr. Stig Ogata | Vice President of Corporate Communications | N/A | N/A | N/A |
Ms. Collette Taylor | Senior Vice President of Human Resources | N/A | N/A | 1963 |
Ms. Tatjana Dragovic | Senior VP and Head of Ethics & Compliance | N/A | N/A | N/A |
Mr. Nobuaki Tanaka | President of Japan Commercial & Senior Corporate Executive | N/A | N/A | N/A |
Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex's GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan.
Astellas Pharma Inc.’s ISS governance QualityScore as of 29 April 2024 is 2. The pillar scores are Audit: 1; Board: 2; Shareholder rights: 6; Compensation: 1.